Clinical Trials

21 results for Bladder Cancer

Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

  • Condition: Healthy Control, Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bl
  • Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
  • Study ID: NCT01050504
View Trial

A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma

  • Condition: Cancer
  • Intervention: Drug: GSK3326595 Capsules
  • Study ID: NCT02783300
View Trial

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney

  • Condition: Urothelial Cancer, Cancer, Bladder Neoplasms, Urinary Bladder Cancer
  • Study ID: NCT00872495
View Trial

Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Urothelial Cancer: A Multicenter Randomized Phase II Study of Two Alternative Dosing Schedules

  • Condition: Urothelial Carcinoma, Locally Advanced, Unresectable
  • Intervention: Drug: Atezolizumab, Drug: Gemcitabine, Drug: Cisplatin
  • Study ID: NCT03093922
View Trial

A Phase 1b, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR 214 and Anti-PD-L1 (Atezolizumab) in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer

  • Condition: Non-Small Cell Lung Cancer, Urinary Bladder Neoplasms, Neoplasm Metastasis
  • Intervention: Drug: Combination of NKTR-214 + atezolizumab
  • Study ID: NCT03138889
View Trial

Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study -

  • Condition: Bladder Cancer, Ureter Cancer, Urethral Cancer, Transitional Cell Carcinoma
  • Intervention: Drug: Treatment duration of cisplatin based chemotherapy
  • Study ID: NCT03296306
View Trial

A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

  • Condition: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
  • Intervention: Drug: Gemcitabine Hydrochloride, Drug: Cisplatin, Biological: Pegfilgrastim, Procedure: Conventional Surgery, Procedure: Radical Cystectomy, Other: Chemoradiotherapy
  • Study ID: NCT03609216
View Trial

A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma

  • Condition: Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
  • Intervention: Drug: Sitravatinib, Drug: Nivolumab
  • Study ID: NCT03606174
View Trial

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers

  • Condition: Non-metastatic Muscle Invasive Bladder Cancer
  • Intervention: Drug: Avelumab, Procedure: cystectomy, Combination Product: CG, Combination Product: DD-MVAC, Combination Product: PG
  • Study ID: NCT03674424
View Trial

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

  • Condition: Metastatic Urothelial Carcinoma, Bladder Cancer
  • Intervention: Drug: Cabozantinib, Drug: Pembrolizumab
  • Study ID: NCT03534804
View Trial

Gemcitabine-cisplatin Plus Avelumab or Gemcitabine-cisplatin as First-line Treatment of Patients With Locally Advanced or Metastatic Urothelial Bladder Carcinoma (GCISAVE)

  • Condition: Bladder Carcinoma
  • Intervention: Drug: Avelumab, Drug: GC
  • Study ID: NCT03324282
View Trial

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

  • Condition: Acinar Cell Carcinoma, Adrenal Cortex Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Appendix Mucinous Adenocarcinoma, Bladder Adenocarcinoma, Bronchioloalveolar Carcinoma, Ce
  • Intervention: Procedure: Biospecimen Collection, Biological: Ipilimumab, Biological: Nivolumab
  • Study ID: NCT02834013
View Trial

A Prospective, Single Arm, Multicenter, Phase II-Trial to Assess Safety and Efficacy of Preoperative RAdiation Therapy Before Radical CystEctomy Combined With ImmunoTherapy in Locally Advanced Urothelial Carcinoma of the Bladder

  • Condition: Urinary Bladder Cancer
  • Intervention: Drug: Nivolumab, Radiation: Radiation therapy of the pelvis, Procedure: Radical cystectomy with standardized pelvic lymphadenectomy
  • Study ID: NCT03529890
View Trial

Phase II Trial of Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients With Advanced Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Radiation: Radiation Therapy
  • Study ID: NCT03486197
View Trial

A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma

  • Condition: Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, PD-L1 Positive, Stage III Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder
  • Intervention: Biological: Pembrolizumab, Drug: Tazemetostat
  • Study ID: NCT03854474
View Trial

A Phase II Trial to Evaluate Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient Advanced Urothelial Cancer

  • Condition: Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Infiltrating Bladder Urothelial Carcinoma,
  • Intervention: Drug: Avelumab, Drug: Pemetrexed
  • Study ID: NCT03744793
View Trial

A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics

  • Condition: Bladder Cancer
  • Intervention: Drug: Abemaciclib
  • Study ID: NCT03837821
View Trial

Phase II Study of Avelumab in Combination With AXL Inhibitor AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Avelumab, Drug: AVB-S6-500
  • Study ID: NCT04004442
View Trial

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

  • Condition: Urothelial Cancer
  • Intervention: Drug: Enfortumab vedotin, Drug: Pembrolizumab, Drug: Cisplatin, Drug: Carboplatin, Drug: Gemcitabine
  • Study ID: NCT04223856
View Trial

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)

  • Condition: Urothelial Carcinoma, Bladder Cancer, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Cancer, Transitional Cell Carcinoma
  • Study ID: NCT04527991
View Trial

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

  • Condition: Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, Breast Neoplasms
  • Study ID: NCT04579380
View Trial